J Stroke Search

CLOSE


J Stroke > Volume 25(3); 2023 > Article
Baik, Shim, Gwak, Kim, Nam, Jeon, Lee, and Heo: Patent Foramen Ovale May Decrease the Risk of Left Atrial Thrombosis in Stroke Patients With Atrial Fibrillation
Dear Sir:
Atrial fibrillation (AF) and patent foramen ovale (PFO) are potential causes of stroke [1-3]. When a patient has both AF and PFO, the risk of stroke/thromboembolism from one of these conditions may be affected by the other [4]. However, this issue has rarely been investigated.
AF is often accompanied by left atrial (LA)/LA appendage (LAA) thrombus and spontaneous echo contrast (SEC), which increase the risk of embolism [1,2,5] and are associated with poor clinical outcomes in stroke patients [6]. Blood stasis in the LA/LAA is the main mechanism for developing LA/LAA thrombus and SEC in patients with AF [1,2]. Although shunt flow through the PFO may also affect LA/LAA hemodynamics [7], whether PFO influences LA/LAA thrombosis remains unclear. This study investigated the risk of LA/LAA thrombus or SEC in stroke patients with both AF and PFO.
This single-center retrospective cross-sectional study included patients with acute ischemic stroke who had nonvalvular AF and underwent transesophageal echocardiography (TEE) between 2011 and 2019 [4]. Patients who received LAA occlusion or PFO closure were excluded. The presence of PFO, LA/LAA thrombus, and SEC was determined using TEE. The measured echocardiographic parameters were LAA emptying velocity (LAAV), LA volume index, left ventricular ejection fraction, and ratio of early diastolic mitral inflow velocity to early diastolic mitral annular tissue velocity. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System (no. 4-2022-1131), and the need for informed consent was waivered owing to its retrospective nature. Detailed information on the study population and echocardiographic evaluation are presented in the Supplementary Methods. Statistical analysis was performed using R version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.4 (SAS Institute, Cary, NC, USA). Multivariable logistic regression analyses were performed to compare the frequencies of LA/LAA thrombus or SEC between patients with and without PFO. Mediation analysis was performed to evaluate echocardiographic parameters for explaining the relationship between PFO and LA/LAA thrombus or SEC [8].
Of the 1,469 stroke patients with AF, 696 with nonvalvular AF who underwent both TEE and TTE were included (Supplementary Figure 1) (median age=73 years, 59.2% male). Among them, 145 (20.8%) had PFO. LA/LAA thrombus or SEC was observed in 331 (47.6%) patients (thrombus in 82 [11.8%] and SEC in 321 [46.1%]).
LA/LAA thrombus or SEC was less frequent in patients with PFO than in those without (37.2% vs. 50.3%, P=0.007) (Table 1). In multivariable backward regression analysis, PFO was independently associated with a lower prevalence of LA/LAA thrombus or SEC (adjusted odds ratio [OR] 0.65, 95% confidence interval [CI] 0.44-0.96, P=0.028) (Table 2 and Supplementary Table 1). Additionally, PFO with high-risk features (a large shunt or atrial septal aneurysm) showed a stronger association (OR 0.39, 95% CI 0.16-0.94, P=0.037) (Table 2). LAAV was significantly higher in patients with PFO than in those without (35.0 [21.8-53.0] cm/s vs. 27.6 [18.3-46.5] cm/s, P=0.005) (Table 1).
In the mediation analysis of echocardiographic parameters, LAAV was the only significant mediator for the effect of PFO on LA/LAA thrombus or SEC (91.1% mediation, P=0.031) (Figure 1 and Supplementary Table 2). The mediating effect was stronger in PFO patients with high-risk features (95.5% mediation, P=0.001) (Supplementary Table 3).
This study showed that PFO was associated with a lower prevalence of LA/LAA thrombus or SEC in stroke patients with nonvalvular AF, with the relationship likely to be mediated by higher LAAV.
In this study, LA/LAA thrombus or SEC was less frequent in patients with PFO than in those without. This result is in line with those of a previous study, which showed that LA/LAA thrombus or SEC was less frequent in patients with severe mitral stenosis and a coexisting PFO [9]. Although the cause-effect relationship remains uncertain, these findings suggest that PFO has a beneficial role in reducing LA/LAA thrombosis in patients with heightened thrombotic conditions. Stroke patients with determined etiologies, including AF, had a lower risk of recurrent stroke when they had a PFO [4]. It was speculated that PFO might be the actual etiology of stroke in some patients; therefore, the generally low-recurrence risk in PFO-associated stroke might be related to the decreased risk of stroke recurrence in such patients [4]. However, other factors may also be responsible for this low stroke risk. In AF, the presence of LA/LAA thrombus or SEC is an indicator of increased stroke risk [1,2]. Our findings suggest that coexisting PFO in patients with AF may reduce the risk of thromboembolism.
We also found that LAAV was significantly higher in patients with PFO than in those without. LAAV is a quantitative parameter for estimating thromboembolic risk, and a low LAAV has been associated with a higher risk of LA/LAA thrombus or SEC and thromboembolism [1,2]. Our findings suggest that intermittent shunt flow through the PFO may affect the flow dynamics in the LA/LAA, which was exhibited as a higher LAAV. These flow changes may act favorably to reduce blood stasis within the LA/LAA in patients with AF.
In this study, the decreased risk of LA/LAA thrombus or SEC in patients with PFO was almost exclusively explained by the increased LAAV. The mediating effect was stronger in PFO patients with high-risk features. Atrial remodeling and blood stasis are the key mechanisms of thrombosis in AF [1,2]. Considering the crucial role of slow flow in LA/LAA in thrombosis [1,2] and similar other demographic and clinical factors between patients with and without PFO, PFO-related changes in the LAAV may have played a major role in lowering the risk of thrombosis in this study population.
Ischemic stroke may recur even after PFO closure, and AF is a known potential procedure-related complication after PFO closure [7,10]. Our findings suggest that measuring LAAV may be necessary in patients undergoing PFO closure because the procedure may further decrease LAAV in patients with low LAAV, thereby may increasing the risk of LA thrombosis and ischemic stroke.
This study had several limitations. TEE could not be performed in nearly half of the stroke patients because of the requirement for patient cooperation. Consequently, this study included patients with milder strokes (Supplementary Table 4). The generalizability of the findings of this study may be limited because they were based on data from a single university hospital with a single ethnicity.
In conclusion, coexisting PFO decreased the risk of LA/LAA thrombus or SEC in stroke patients with AF, mainly by reducing blood stasis.

Supplementary materials

Supplementary materials related to this article can be found online at https://doi.org/10.5853/jos.2023.01179.
Supplementary Table 1.
Predictors for left atrial thrombus or SEC
jos-2023-01179-Supplementary-Table-1.pdf
Supplementary Table 2.
Analysis of potential echocardiographic mediators of the effect of a patent foramen ovale on left atrial thrombus or spontaneous echo contrast
jos-2023-01179-Supplementary-Table-2.pdf
Supplementary Table 3.
Analysis of potential echocardiographic mediators of the effect of PFO on left atrial thrombus or spontaneous echo contrast according to PFO with and without high-risk features*
jos-2023-01179-Supplementary-Table-3.pdf
Supplementary Table 4.
Comparison of patients in whom TEE was performed or not performed
jos-2023-01179-Supplementary-Table-4.pdf
Supplementary Figure 1.
Patient selection. LAA, left atrial appendage; PFO, patent foramen ovale; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography
jos-2023-01179-Supplementary-Fig-1.pdf

Notes

Funding statement
This study was supported by the National Research Foundation of Korea, which is funded by the Korean government (No. 2021R1A2C2003658) and a faculty research grant from Yonsei University College of Medicine (6-2022-0047).
Conflicts of interest
MB report research grants from Daewoong Pharmaceutical. All other authors report no potential conflicts of interest.
Author contribution
Conceptualization: MB, JHH. Study design: MB, JHH. Methodology: MB, CYS, SYG, JHH. Data collection: MB, CYS, SYG, YDK, HSN, JHH. Investigation: MB, JHH. Statistical analysis: MB, SJ, HSL. Writing—original draft: MB, JHH. Writing—review & editing: MB, CYS, SYG, YDK, HSN, JHH. Funding acquisition: MB, JHH. Approval of final manuscript: all authors.

Figure 1.
Mediation of effects of PFO on LA/LAA thrombus or SEC. Pathway of mediation analysis showing how echocardiographic parameters mediate the effect of PFO on LA/LAA thrombus or SEC. (A) The direct effect of PFO on LA/LAA thrombus or SEC and (B) LAAV mediation of the effect of PFO on LA/LAA thrombus or SEC. Comparable coefficients: a, the effect of PFO on LAAV; b, effect of LAAV on LA/LAA thrombus or SEC; c, direct association between PFO and LA/LAA thrombus or SEC (without adjusting for LAAV); and c’, association between PFO and LA/LAA thrombus or SEC adjusting for LAAV. The degree of mediation is shown as Baron and Kenny’s proportion of effect mediation (%). PFO, patent foramen ovale; LA, left atrial; LAA, left atrial appendage; SEC, spontaneous echo contrast; LAAV, left atrial appendage emptying velocity. *P<0.05.
jos-2023-01179f1.jpg
Table 1.
Comparison of characteristics between patients with and without PFO
PFO (n=145) No PFO (n=551) P
Demographics
Age (yr) 73.0 [62.0-78.0] 73.0 [66.0-79.0] 0.258
Male sex 94 (64.8) 318 (57.7) 0.145
Hypertension 111 (76.6) 442 (80.2) 0.392
Diabetes 41 (28.3) 177 (32.1) 0.431
Dyslipidemia 26 (17.9) 103 (19.0) 0.869
Old ischemic stroke 24 (16.6) 101 (18.3) 0.708
Congestive heart failure 7 (4.8) 49 (8.9) 0.153
Ischemic heart disease 54 (37.2) 185 (33.6) 0.466
Current smoker 17 (11.7) 72 (13.1) 0.771
CHA2DS2-VASc score 3.0 [2.0-4.0] 4.0 [2.0- 5.0] 0.062
NIHSS at admission 4.0 [1.0-10.0] 4.0 [1.0-10.0] 0.401
Anticoagulation 23 (15.9) 136 (24.7) 0.032
Echocardiography parameters
LAAV (cm/s) 35.0 [21.8-53.0] 27.6 [18.3-46.5] 0.005
LVEF (%) 54.0 [50.0-59.0] 56.0 [50.0-61.0] 0.162
LAVI (mL/m2) 48.1 [37.6-61.2] 51.0 [39.5-65.0] 0.113
E/E’ 12.5 [10.0-15.1] 13.0 [10.0-16.3] 0.272
LA/LAA thrombus or SEC 54 (37.2) 277 (50.3) 0.007
Values are presented as median [interquartile range] or number (%).
PFO, patent foramen ovale; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65 to 74, and sex category (female); NIHSS, National Institutes of Health Stroke Scale; LAAV, left atrial appendage emptying velocity; LVEF, left ventricular ejection fraction; LAVI, left atrial volume index; E/E’, early diastolic mitral inflow velocity to early diastolic mitral annulus velocity; LA, left atrial; LAA, left atrial appendage; SEC, spontaneous echo contrast.
Table 2.
Prediction of left atrial thrombus or SEC according to PFO and high-risk features*
Univariable
Multivariable Model 1
Multivariable Model 2
Multivariable Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
PFO (vs. no PFO)
PFO 0.59 (0.40-0.85) 0.006 0.61 (0.42-0.90) 0.012 0.65 (0.44-0.96) 0.029 0.65 (0.44-0.96) 0.028
PFO considering high-risk features
No PFO 1 (reference) 1 (reference) 1 (reference) 1 (reference)
PFO without high-risk features 0.66 (0.44-0.996) 0.048 0.68 (0.45-1.02) 0.063 0.72 (0.47-1.10) 0.125 0.72 (0.48-1.10) 0.130
PFO with high-risk features 0.33 (0.14-0.79) 0.013 0.38 (0.16-0.92) 0.031 0.39 (0.16-0.96) 0.041 0.39 (0.16-0.94) 0.037
Logistic regression analysis was performed to determine the association between PFO, and LA/LAA thrombus or SEC. Model 1 was adjusted for age, male sex, and CHA2DS2-VASc score. Model 2 was adjusted for Model 1 factors, along with hypertension, diabetes, dyslipidemia, old ischemic stroke, congestive heart failure, ischemic heart disease, current smoking, and anticoagulation. Model 3 was adjusted using a backward regression analysis.
SEC, spontaneous echo contrast; PFO, patent foramen ovale; OR, odds ratio; CI, confidence interval; LA, left atrial; LAA, left atrial appendage; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, stroke (doubled), vascular disease, age 65 to 74, and sex category (female).
* High-risk features indicate the presence of either an atrial septal aneurysm or a large-shunt size. [3]

References

1. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994;23:961-969.
crossref pmid
2. Mügge A, Kühn H, Nikutta P, Grote J, Lopez JA, Daniel WG. Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 1994;23:599-607.
crossref pmid
3. Elgendy AY, Saver JL, Amin Z, Boudoulas KD, Carroll JD, Elgendy IY, et al. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke. JAMA Neurol 2020;77:878-886.
crossref pmid
4. Baik M, Shim CY, Gwak SY, Kim YD, Nam HS, Lee HS, et al. Patent foramen ovale and risk of recurrence in stroke of determined etiology. Ann Neurol 2022;92:596-606.
crossref pmid pdf
5. Bang OY, Park KM, Jeong DS. Occurrence of ischemic stroke in patients with atrial fibrillation receiving non-vitamin K oral anticoagulants: causes and prevention strategies. J Stroke 2023;25:199-213.
crossref pmid pmc pdf
6. Heo J, Lee H, Lee IH, Nam HS, Kim YD. Impact of left atrial or left atrial appendage thrombus on stroke outcome: a matched control analysis. J Stroke 2023;25:111-118.
crossref pmid pmc pdf
7. Vandenberk B, Morillo CA. Atrial fibrillation after transcatheter patent foramen ovale closure: to measure is to know. Heart Rhythm 2022;19:1421-1422.
crossref pmid
8. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173-1182.
crossref pmid
9. Babur Guler G, Dogan AC, Kalkan AK, Demir AR, Uygur B, Birant A, et al. Does patent foramen ovale presence procure favourable outcomes in patients with severe rheumatic mitral stenosis? Int J Cardiovasc Imaging 2021;37:2871-2879.
crossref pmid pdf
10. Kawano H, Honda Y, Johno T, Maruoka H, Nakanishi K, Saito M, et al. Antiplatelet therapy may be insufficient to prevent stroke recurrence before percutaneous patent foramen ovale closure. J Stroke 2023;25:307-310.
crossref pmid pmc pdf


ABOUT JoS
AUTHOR INFORMATION
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
Editorial Office
Department of Neurology, Asan Medical Center,Ulsan University College of Medicine
88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org
Website and system ⟫ E-mail: journal@m2community.co.kr
Publishing company ⟫ E-mail: ka72sus@smileml.com
Developed in M2PI
Copyright © 2024 by Korean Stroke Society.
Close layer
prev next